Heme
Advertisement
The hepcidin mimetic increased hematocrit control and reduced both phlebotomy need and symptoms in a phase 2 trial.
PGK1 antibody levels in patients with recovered immuno-related pancytopenia were negatively correlated with platelet levels.
Thrombosis history was not predictive of overall survival in patients with pulmonary hypertension risk and PV, a study found.
The oral agent exhibited promising hemoglobin response performance and safety in this stage of an ongoing phase 2/3 study.
The first-in-class agent operates by increasing both von Willebrand factor and factor VIII levels in patients.
Immune thrombocytopenia featured most prominently at the Meeting but new data was presented for several forms of the disease.
Imetelstat is indicated for patients with lower-risk MDS who had an unsatisfactory response to or are ineligible to ESAs.
In findings arterial thrombosis carried worse overall survival than venous thrombosis in this patient population.
CTD402 will enter a single-arm, open-label, phase 1b/2 trial aimed to optimize dosing and accelerate clinical development.
Clinical trials are ongoing to evaluate this orally available, selective inhibitor of XPO1 as part of combination regimens.
The panel's discussion, moderated by Neil Love, MD, dove especially into the nuances of using avapritinib and ruxolitinib.
Thomas Martin, MD, presented data on CAR-T, bispecifics, and BCMAs in MM the National General Medical Oncology Summit.
Neil Love, MD, has moderated an expert panel discussing current practice and recent data behind these treatments for NHL.
Anthony Sochet, MD, MS, on Knowledge Gaps Affecting Pediatric Inpatient Thromboprophylaxis Decisions
Clinical data is limited in areas such as how to evaluate bleeding risk and when to apply mechanical thromboprophylaxis.
Clinical trials are ongoing of linvoseltamab as monotherapy or in combination therapy for relapsed or refractory disease.
Detectable MRD before HSCT is associated with worse survival in patients with MDS/MPN compared with undetectable MRD.
A phase 1 clinical trial is planned to test the safety and tolerability of AUTX-703 in patients with AML.
This bispecific antibody is under investigation for multiple types of B-cell non-Hodgkin lymphoma in ongoing clinical trials.
Overall survival, nonrelapse mortality, and relapse rates were also assessed in the phase 2 trial which had these results.
Adding ruxolitinib before, during, and after HSCT reduced the incidence of GVHD among patients with myelofibrosis.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.